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same size. As a ﬁrst step, regression analysis in the full sample
was performed, where VAS assessment (0–100) of actual health
state constituted the dependent variable and dichotomized (some
problem/considerable problem) answers on the ﬁve dimensions
the independent. After excluding outliers, (standardized [z-]
residuals <-2.5 or >2.5), ten pairs of analyses were performed,
excluding one part of the sample at the time. From the ﬁrst analy-
sis in each pair, outliers were excluded and the second analysis
was performed. The coefﬁcients gained in the second analysis
were used to calculate Jackknife estimates of “true” coefﬁcients.
RESULTS: The model estimated constant of 89.7 and coefﬁcients
for each dimension assessed as having “some problem” (self care:
-15.89; mobility: -10.30; usual activities: -9.52; depression: 
-7.87; pain/discomfort: -7.49) and for having “considerable
problem” with pain/discomfort: -6.00; usual activities: -8.09;
depression: -33.66 and on any of dimensions: -20.18. Interac-
tions did not increase explanatory value of the analysis. 
CONCLUSIONS: Based on this model, the most important
determinant of health status value (utility) for the Swedish pop-
ulation is depression, followed by problems with mobility and
self-care. Pain/discomfort is the least important, regardless of the
magnitude of the problems were assessed.
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OBJECTIVES: To assess to what extent QoL results obtained
through a generic instrument (EQ-5D) correlate with those cap-
tured by a disease-sensitive measure (QoL-Assessment of Growth
Hormone Deﬁciency in Adults). METHODS: Data were col-
lected through a mailing survey to a random sample (n = 2990)
of the Swedish population. The questionnaire comprised EQ-5D
and QoL-AGHDA. QoL-AGHDA is a 25-item measure that
elicits yes/no responses to personal statements describing prob-
lems that characterize aspects of HrQoL in growth hormone deﬁ-
ciency. A high QoL-AGHDA score denotes poor HrQoL. EQ-5D
is a well-known and widely recognized generic instrument.
(EuroQoL Group, 1990). The response rate was 65% and com-
plete data on EQ-5D and QoL-AGHDA were obtained from
1665 (48.2% males; mean age 49.5, range 18–85 years) respon-
dents. RESULTS: For EQ-5D dimensions: 11% respondents
reported problems with mobility, 2% with self care, 9% usual
activities, 46% pain/discomfort and 30% anxiety/depression. All
results were weighted to represent the Swedish population proﬁle
with respect to age and gender. The mean EQ-5D VAS score was
80 (SD 17.3) and the mean QoL-AGHDA score was 3.9 (SD
4.8). There was a signiﬁcant correlation between QoL-AGHDA
scores and EQ-5D VAS (r = -0.56, p < 0.001). CONCLUSIONS:
These results show that there is strong correlation between
results generated by a disease-sensitive and a generic measure,
and thus suggest that using generic instruments for QoL assess-
ments in speciﬁc conditions yield reliable results that could be
employed for pharmacoeconomic evaluations.
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OBJECTIVES: Measuring the cost-effectiveness of interventions
for adult growth hormone deﬁciency (AGHD) requires estimates
of the beneﬁts. For the purposes of cost-utility analysis those ben-
eﬁts should be expressed as QALYs. Where primary outcomes
data are collected using condition-sensitive measures of health-
related quality of life (HrQoL) then recalibration is necessary.
This paper reports the use of EQ-5D as a mechanism for con-
verting such data into a useable QALY metric. METHODS:
QoL-AGHDA is a 25-item questionnaire designed for use in
AGHD. Yes/no responses are used to compute a summary index
with a high score denoting poor HrQoL. A total of 1000 indi-
viduals randomly selected from the UK Population Preference
Panel were sent a copy of QoL-AGHDA together with EQ-5D,
a widely used generic measure of HrQoL calibrated in terms of
TTO preference weights. Corresponding QoL-AGHDA data on
patients (n = 836) was made available from UK KIMS (Pﬁzer
International Metabolic Database). RESULTS: Completed
survey forms were received from 882 individuals (57% female,
median age 55). There was a high degree of correlation between
EQ-5D and QOL-AGHDA summary score (r = -0.529, p <
0.001). Age/gender standardised mean EQ-5D index scores were
computed for different categories of QoL-AGHDA score in the
general population survey. These were used as a lookup table to
provide estimates of EQ-5D for each patient in the KIMS dataset
according to their age/gender and QoL-AGHDA score. Within-
year QALY losses between the EQ-5D index for KIMS patients
and corresponding EQ-5D for the general population. Using 
age-speciﬁc prevalence data together with the relevant popula-
tion life expectancy tables, it was also possible to estimate poten-
tial lifetime QALY losses for GHD. CONCLUSIONS: AGHD
patients record lower levels of HrQoL than the general popula-
tion. This difference equates to a 0.15 QALY “loss” per annum
and a lifetime loss across all GHD patients of some 40,000
QALYs.
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There is conﬂicting evidence about whether reduced height
results in ill health. OBJECTIVE: The objective of this study was
to determine if there exists an association between height and
health-related utility (EQ5Dindex). METHODS: This was a retro-
spective study of two large health data sources that recorded
height and other anthropomorphic parameters along with the
EQ5Dindex. The ﬁrst a national survey in the general population
(English Health Survey, 1996), the second an ongoing study to
characterise outcome in hospital treated patients (the Health
Outcomes Data Repository [HODaR]). Both of these sources
had large numbers of observations, thus dealing with the wide
variability in factors leading to ill health potentially confound-
ing or masking any association. RESULTS: There was a direct
association between height and the EQ5Dindex. This association
was logarithmic; the gradient was more marked in shorter 
subjects. The association was signiﬁcant. On average, a 10cm
increase in height resulted in 0.01 more EQ5Dindex units in men
and 0.02 in women (standardized for age and ethnicity). This
association appeared to be independent of confounding factors
such as body mass, where shorter people had in all BMI cate-
gories lower health utility than taller people. An increase in
height from the ninth centile to the eighth equated to a utility
gain of 0.021 in men and 0.025 in women. A shift from the third
centile to the second equated to a utility gain of 0.007 in men
